These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27470607)

  • 1. Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy.
    Arslan B; Onuk Ö; Hazar İ; Aydın M; Çilesiz NC; Eroglu A; Nuhoglu B
    Tumori; 2017 Mar; 103(2):204-208. PubMed ID: 27470607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The meaning of PSA progression after radical prostatectomy. Preliminary results].
    Luján Galán M; Pascual Mateo C; Rodríguez García N; Chiva Robles V; Escalera Almendros C; Angulo Cuesta J; Berenguer Sánchez A
    Actas Urol Esp; 2006 Apr; 30(4):353-8. PubMed ID: 16838606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The factors predicting biochemical recurrence in patients with radical prostatectomy.
    Koca O; Ün S; Türk H; Zorlu F
    Arch Ital Urol Androl; 2016 Jan; 87(4):270-5. PubMed ID: 26766796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
    Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
    Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
    Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
    Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
    Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
    Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy.
    Barlow LJ; Badalato GM; Bashir T; Benson MC; McKiernan JM
    BJU Int; 2010 Jun; 105(12):1646-9. PubMed ID: 19863523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.